Frontiers in pediatrics · 2025
Metabolic changes in children with idiopathic central precocious puberty after gonadotrophin-releasing hormone agonist therapy: a meta-analysis.
СтатьяСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Bo, Qu Xia, Wang Jianhong, Xu Qi, Zhang Lili, Wang Xi, Peng Nan, Gu Jialu, Zhang Xiaoqian, Wang Qiong, Niu Wenquan, Wang Lin
Аннотация
BACKGROUND: We aimed to assess the effects of gonadotrophin-releasing hormone agonist (GnRHa) therapy on metabolic changes by synthesizing results from clinical trials involving children with idiopathic central precocious puberty (ICPP).
METHODS: Literature search, trial selection, data extraction and quality assessment were completed independently by two investigators. STATA software (version 14.1) was used for data analyses. Effect-size estimates are expressed as weighted mean difference (WMD) with 95% confidence interval (CI).
RESULTS: This meta-analysis was conducted based on 19 clinical trials and 1,553 ICPP children. Overall analyses showed that for body mass index standard deviation score (BMISDS), no significance was noted after administering GnRHa to children with ICPP (WMD: -0.08; 95% CI: -0.22-0.06; p = 0.269). Similarly, no significance was noted for total cholesterol (WMD: 1.94 mg/dl; 95% CI: -10.29-14.17; p = 0.756), triglyceride (WMD: -5.31 mg/dl; 95% CI: -26.92-16.29; p = 0.630) and low-density lipoprotein (WMD: -9.63 mg/dl; 95% CI: -40.09-20.83; p = 0.535). By contrast, a statistically higher high-density lipoprotein of 7.07 mg/dl after administering GnRHa to children with ICPP (95% CI: 3.00-11.14; p = 0.001). Subgroup and meta-regression analyses revealed that initial body weight, sample size, and age were significant sources of between-trial heterogeneity. There was a low probability of publication bias for above comparison, as indicated by Egger's tests.
CONCLUSIONS: Our meta-analytical findings indicate that GnRHa treatment did not appear to increase BMI and lipid metabolism levels in children with ICPP, irrespective of obesity status at the time of initiation therapy.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO (CRD42023410554).
METHODS: Literature search, trial selection, data extraction and quality assessment were completed independently by two investigators. STATA software (version 14.1) was used for data analyses. Effect-size estimates are expressed as weighted mean difference (WMD) with 95% confidence interval (CI).
RESULTS: This meta-analysis was conducted based on 19 clinical trials and 1,553 ICPP children. Overall analyses showed that for body mass index standard deviation score (BMISDS), no significance was noted after administering GnRHa to children with ICPP (WMD: -0.08; 95% CI: -0.22-0.06; p = 0.269). Similarly, no significance was noted for total cholesterol (WMD: 1.94 mg/dl; 95% CI: -10.29-14.17; p = 0.756), triglyceride (WMD: -5.31 mg/dl; 95% CI: -26.92-16.29; p = 0.630) and low-density lipoprotein (WMD: -9.63 mg/dl; 95% CI: -40.09-20.83; p = 0.535). By contrast, a statistically higher high-density lipoprotein of 7.07 mg/dl after administering GnRHa to children with ICPP (95% CI: 3.00-11.14; p = 0.001). Subgroup and meta-regression analyses revealed that initial body weight, sample size, and age were significant sources of between-trial heterogeneity. There was a low probability of publication bias for above comparison, as indicated by Egger's tests.
CONCLUSIONS: Our meta-analytical findings indicate that GnRHa treatment did not appear to increase BMI and lipid metabolism levels in children with ICPP, irrespective of obesity status at the time of initiation therapy.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO (CRD42023410554).